A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Exclusion Criteria

• •2. No prior systemic treatment for metastatic NSCLC.
• •3. Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).
• •4. Tumors with PD-L1 expressed in ≥ 50% tumor cells.
• •5. At least 1 measurable lesion as defined per RECIST v1.1.
• •6. ECOG Performance Status ≤ 1.
• •1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
• •2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
• •3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
• •4. Active autoimmune diseases or history of autoimmune diseases that may relapse.